[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-tachycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-tachycardia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,81,104,129,154,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100440400","baseline-atrial-fibrosis-predicts-risk-for-post-operative-atrial-fibrillation-in-patients-undergoing-cardiac-surgery-100440400",false,"NCT05014802","Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: A Pilot Study for SAPPORO-AF","Inclusion Criteria:\n\n* Male or female patients age 40 years of age or older\n* Patients with no history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) scheduled to undergo cardiac surgery (These surgeries include but are not limited to coronary artery bypass graft (CABG), valvular repair\u002Freconstruction, aneurysm repair, and insertion of pacemaker).\n\nExclusion Criteria:\n\n* Patients with a history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia)\n* Patients with a history of cardiac or open chest surgery\n* Patients with a history of catheter ablation\n* Patients under the age of 40\n* Patients with left ventricular assist device (LVAD) or scheduled to have LVAD implanted\n* Patients who have previously undergone extracorporeal membrane oxygenation (ECMO)\n* Patients who have undergone or will undergo heart transplantation\n* Patients with any health related Late Gadolinium Enhancement (LGE)-MRI contraindications (including previous allergic reaction to gadolinium, pacemakers, defibrillators, other devices\u002Fimplants contraindicated for MRI)\n* Acute or chronic severe renal disease with a low glomerular filtration rate (GFR), \\\u003C30 mL per minute per 1.73 m2 will be excluded from the trial. (A creatinine measurement should be available within the last 6 months. If not, a creatinine blood test will be drawn to assess for renal function before the MRI acquisition).\n* Patients weighing \\> 300 lbs. (MRI image quality decreases due to increased body mass index)\n* Patients currently pregnant or breastfeeding, or plan to become pregnant during the study period\n* Patients with cognitive impairment preventing them from giving informed consent will be excluded from the study\n* Patients who cannot read, speak, and\u002For understand English","ALL","40 Years","120 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The study aims to evaluate and compare the incidence of atrial arrhythmias (including Post-Operative Atrial Fibrillation (POAF), atrial flutter, and atrial tachycardia) stratified by baseline Utah fibrosis stages and overall fibrosis (%) of the left atrial wall area. The investigators hypothesize that patients with a higher baseline Utah fibrosis staging will experience a higher incidence of POAF.\n\nThe study also aims to evaluate and compare the in-hospital mortality, length-of-stay (LOS), complication rates (strokes, pneumonia, respiratory failure etc.) of the different Utah fibrosis stage cohorts. Perform cost analysis and compare between patients with POAF and patients without POAF. The investigators hypothesize that patients experiencing POAF will have a higher mortality rate, longer LOS, greater complications, and therefore, additional hospital costs.",[25,26,27,28],"Atrial Fibrillation","Atrial Arrhythmia","Atrial Flutter","Atrial Tachycardia",[30,31,32],"Atrial Fibrosis","Cardiac Magnetic Resonance Imaging","Cardiac surgery","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2021-11-21",{"date":41,"type":21},"2026-12",{"name":43,"class":44},"Tulane University","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100457650","ablation-of-consecutive-atrial-tachycardia-100457650","NCT05239364","Ablation of Consecutive Atrial Tachycardia","Ablation of CONseCutive atriaL Tachycardia gUided by Ultra-high-DEnsity Mapping","CONCLUDE","Inclusion Criteria:\n\n* Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery\n* Surface ECG-documentation of AT as primary clinical arrhythmia\n* ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* No previous atrial fibrillation ablation procedure or cardiac surgery\n* Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment\n* History of hemorrhagic diathesis or other coagulopathies\n* Contraindications for oral anticoagulation\n* Hyper- or hypothyroidism\n* Has any condition that would make participation not be in the best interest of the subject","18 Years",{"count":56,"type":21},100,"INTERVENTIONAL",[59],"NA","Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.",[62,63,64,28],"Heart Arrhythmia","Heart Diseases","Arrhythmias, Cardiac",[66,67,68,69,70],"Atrial fibrillation","Atrial tachycardia","Pulmonary vein isolation","Electroanatomical mapping","High density mapping","2026-04-27",{"date":73,"type":37},"2026-04-30",{"date":75,"type":37},"2020-12-22",{"date":77,"type":21},"2027-06",{"name":79,"class":44},"Evangelical Hospital Düsseldorf",6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100301859","atrial-tachycardia-pacing-therapy-in-congenital-heart-100301859","NCT03209583","ATrial Tachycardia PAcing Therapy in Congenital Heart","AT-PATCH","Inclusion Criteria:\n\n* must have structural CHD, an atrial arrhythmia and an ATD implanted. ATP must be turned on.\n\nExclusion Criteria:\n\n* Other arrhythmias substrates such as Long QT (LQT), hypertrophic Cardiomyopathy (HCM), Catecholaminergic polymorphic ventricular tachycardia (CPVT), Arrhythmogenic Right Ventricular Cardiomyopathy.(ARVC), Brugada \\& patients who undergo transplant, surgical maze, or ablation within 5 years of ATD implantation.",{"count":89,"type":21},300,"Congenital heart disease (CHD) affects approximately 1% of newborns in the US, with 25% of those affected having critical conditions requiring open heart surgery within one year of birth. Surgical and medical advances have allowed many patients to live beyond their fourth and fifth decades of life. Unfortunately, cardiac arrhythmias are a relatively common sequela due to cardiac anomalies and surgical scars in addition to residual volume and pressure load on the heart. Atrial arrhythmias, including sinus node dysfunction and intra-atrial re-entrant tachycardia (IART) are among the more common abnormalities found in adults with repaired CHD. The presence of IART significantly increases morbidity and mortality, and anti-arrhythmic medications have been shown to be a sub-optimal treatment strategy with the majority of patients requiring multi-drug therapy. Catheter ablation procedures remain a treatment option, but are less successful for some patient demographics. In the mid-1990's, pacemakers with atrial anti-tachycardia pacing (ATP) capabilities were developed, primarily for the management of atrial flutter and fibrillation in adults with structurally normal hearts. Given the need for pacemakers in the CHD population to manage sinus node dysfunction and atrioventricular node conduction block, the adoption of atrial anti-tachycardia pacemakers began to gain favor. However, there is limited data available comparing the safety and effectiveness of ATP therapy between various demographics of CHD patients. In the current study, the investigators aim to determine if ATP is an effective treatment strategy for IART, specifically within particular sub-populations of CHD patients. Additionally, investigators hope to delineate any significant differences in efficacy of ATP treatment between adult and pediatric congenital heart patients. The research team will accomplish our goals with a retrospective, multi-center study in which data is collected from existing electronic medical records and pacemaker interrogations. Following data collection, the investigators will employ statistical analyses to determine if certain CHD demographics are statistically significant predictors of ATP therapy outcomes.\n\nThe purpose of this prospective\u002Fretrospective study is to determine how effective atrial anti-tachycardia therapies are with the congenital heart patients who are known to have atrial arrhythmias. As this population ages, we know that arrhythmic burden increases and medications are increased or changed for symptomatic improvement.\n\nPatients will be enrolled at the time of anti tachycardia device (ATD) placement or when device therapies are turned on. Patients will need a minimum of 5 years of clinical history prior to implantation and after implantation (unless patient is very young). Data will be collected both retrospectively and prospectively. The research team will consent patients at the time of clinical evaluations and scheduled follow-ups (usually 3 - 6 months). If therapy is effective, investigators will determine the specific programming which was successful. If therapy was ineffective, investigators will also determine if a change in programing was made and if this improved ATP efficacy. Investigators will also determine the arrhythmia burden. Cardioversion and medications before and after ATD implantation will be the key determinants of arrhythmia burden in this study.",[26,28,92,93],"Congenital Heart Disease","Pacemaker Re-Entrant Tachycardia","2026-03-11",{"date":96,"type":37},"2026-03-13",{"date":98,"type":37},"2018-09-01",{"date":100,"type":21},"2027-09-01",{"name":102,"class":44},"Ian Law",15,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":111,"targetDuration":113,"studyType":22,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100601334","registry-of-atrial-arrhythmia-ablation-procedures-using-pulsed-field-ablation-in-poland-100601334","NCT07109141","Registry of Atrial Arrhythmia Ablation Procedures Using Pulsed Field Ablation in Poland","PFA Registry","Inclusion Criteria:\n\n* Informed consent obtained from the participant\n* Subject is undergoing ablation of an atrial arrhythmia using the PFA\n\nExclusion Criteria:\n\n\\-",{"count":112,"type":21},500,"12 Months","The aim of the described project is to establish a multicenter, nationwide registry of atrial arrhythmia ablation procedures using the Pulsed Field Ablation (PFA) method. These procedures have only recently begun to be performed in several centers across Poland. With proper coordination of the registry, this will enable the consolidation of clinical data and the expansion of knowledge regarding the efficacy and safety of these procedures.",[116,27,28,117,118],"Atrial Fibrillation (AF)","Ablation Techniques","Pulsed Field Ablation","2025-07-31",{"date":121,"type":37},"2025-08-07",{"date":123,"type":37},"2024-08-01",{"date":125,"type":21},"2030-07-01",{"name":127,"class":44},"Wroclaw Medical University",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":57,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100599078","clinical-study-on-the-efficiency-of-rapid-arrhythmia-mapping-using-easystars-high-density-mapping-catheter-applications-100599078","NCT07079813","Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications","Rapid Arrhythm","1. Clinical diagnosis: Ventricular tachycardia (VT)\n\n   * Inclusion criteria:\n\n     1. Patients aged between 18 and 80 years;\n     2. Confirmed diagnosis of ventricular tachycardia (VT) via electrocardiogram (ECG) or 24-hour Holter monitoring;\n     3. The patient has experienced at least one episode of VT in the past 6 months and exhibits symptoms of sustained or paroxysmal ventricular tachycardia;\n     4. The patient meets the criteria for ablation surgery and has clear indications for ablation;\n     5. The patient is in good general health and able to tolerate surgery (no severe underlying heart disease, such as severe heart failure or severe coronary artery disease);\n     6. Voluntarily participates and signs an informed consent form.\n   * Exclusion criteria:\n\n     1. Uncontrolled heart failure (New York Heart Association functional class III-IV);\n     2. History of acute or progressive myocardial infarction;\n     3. Severe pulmonary, hepatic, or renal disease;\n     4. Valvular heart disease or congenital heart disease;\n     5. Excessive use of medications or medication intolerance (e.g., beta-blockers, antiarrhythmic drugs);\n2. Clinical diagnosis: Atrial tachycardia (AT)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with atrial tachycardia (AT) by electrocardiogram (ECG) or Holter monitoring;\n     3. Patients presenting with clinical symptoms such as palpitations, chest tightness, or fatigue;\n     4. Patients diagnosed with persistent or paroxysmal atrial tachycardia and meeting the criteria for ablation therapy;\n     5. Patients who voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease or congenital heart disease;\n     2. Patients with severe left ventricular or right ventricular heart failure;\n     3. Patients with severe systemic diseases, such as liver failure, kidney failure, or tumours;\n     4. Patients with cardiomyopathy or aortic dissection;\n3. Clinical diagnosis: atypical atrial flutter (AFL)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Patients diagnosed with atypical atrial flutter (AFL) via electrocardiogram (ECG) or Holter monitoring;\n     3. Patients with clinical symptoms (e.g., palpitations, chest tightness, fatigue, etc.) that significantly impair their quality of life;\n     4. Patients who meet the criteria for atrial tachycardia ablation and have no other severe comorbidities;\n     5. Voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe heart disease, such as cardiomyopathy or severe valvular disease;\n     2. Patients with severe pulmonary disease, such as pulmonary arterial hypertension;\n     3. Patients with a history of major cardiac surgery (e.g., heart transplantation);\n4. Clinically diagnosed with paroxysmal atrial fibrillation (PAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with paroxysmal atrial fibrillation (PAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Frequent episodes of paroxysmal atrial fibrillation with symptoms such as palpitations, fatigue, and dyspnoea, and meeting the criteria for ablation;\n     4. No other severe cardiac or systemic diseases, and meeting the criteria for ablation;\n     5. Voluntarily participating and signing the informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease, aortic dissection, or cardiomyopathy;\n     2. High-risk patients with a history of anticoagulant therapy or currently receiving anticoagulant therapy (e.g., history of thrombosis or stroke);\n     3. Patients with severe underlying conditions such as cancer or severe diabetes;\n5. Clinical diagnosis: Persistent atrial fibrillation (PsAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with persistent atrial fibrillation (PsAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Atrial fibrillation persisting for more than 7 days and symptoms affecting the patient's quality of life;\n     4. Clear indications for ablation and no other severe comorbidities;\n     5. Voluntarily participating and signing an informed consent form.\n\nExclusion criteria:\n\n1. Presence of severe valvular heart disease or cardiomyopathy;\n2. History of stroke or clinical evidence of thrombus formation;\n3. Severe heart failure (NYHA III-IV class);\n4. High-risk cardiac conditions (e.g., acute myocardial infarction, coronary artery disease); In the above different types of rapid arrhythmias, the inclusion criteria primarily focus on the diagnosis and control of clinical symptoms for different types of arrhythmias, while the exclusion criteria focus on avoiding patients with severe comorbidities or those unable to tolerate surgery. Through this patient screening method, the safety of the study and the accuracy of the data are ensured, thereby enabling a better assessment of the clinical efficacy of the new EasyStars catheter.","80 Years",{"count":89,"type":21},[59],"The primary objective of this study was to evaluate the clinical feasibility, safety, and surgical characteristics of the EasyStars™ High Density Mapping Catheterin in patients with complex arrhythmias.",[141,28,142,143],"Ventricular Tachycardia (VT)","Typical Atrial Flutter","Paroxysmal Atrial Fibrillation (PAF)","NOT_YET_RECRUITING","2025-07-28",{"date":119,"type":37},{"date":148,"type":21},"2025-08-30",{"date":150,"type":21},"2027-12-31",{"name":152,"class":153},"Shanghai MicroPort EP MedTech Co., Ltd.","INDUSTRY",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":57,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100590589","empiric-pulsed-field-pulmonary-vein-isolation-during-atrial-tachycardia-ablation-in-adults-with-congenital-heart-disease-100590589","NCT06969378","Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease","Inclusion Criteria:\n\n* Adult patients (\\>= 18 years of age) with repaired or unrepaired congenital heart disease and a history of sustained (\\>30 seconds) AT\n\nExclusion Criteria:\n\n* History of sustained AF and\u002For previous catheter or surgical pulmonary vein isolation.",{"count":161,"type":21},30,[59],"This is a prospective, single-arm intervention trial whereby we will test the safety and efficacy of performing pulmonary vein isolation (PVI) using pulsed field ablation (PFA) in adult patients with congenital heart disease (CHD) who are presenting for atrial tachycardia (AT) ablation.",[25,28,27,92,165,118,166],"Pulmonary Vein Isolation","Catheter Ablation",[168,169,170,171,172,173,174,175],"atrial fibrillation","atrial tachycardia","atrial flutter","pulsed field ablation","congenital heart disease","adult congenital heart disease","pulmonary vein isolation","catheter ablation","2025-05-05",{"date":178,"type":37},"2025-05-13",{"date":180,"type":21},"2025-07-01",{"date":182,"type":21},"2026-06-30",{"name":184,"class":44},"Boston Children's Hospital",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":193,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":194,"targetDuration":196,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":207,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":128},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",true,{"count":195,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[64,25,27,199,28,200,201,202,203,204,205,206],"Ventricular Tachycardia","Arrhythmogenic Right Ventricular Dysplasia","Long QT Syndrome","Brugada Syndrome","Supraventricular Tachycardia","Catecholaminergic Polymorphic Ventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[166,208,209,210,211,212,206],"Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":215,"type":37},"2025-03-30",{"date":217,"type":37},"2021-03-17",{"date":219,"type":21},"2031-12-31",{"name":221,"class":44},"Universitätsklinikum Hamburg-Eppendorf"]